🔗 Share this article Individuals Coming Off Slimming Jabs Gain Back Weight Four Times Faster Than Dieters Weight management often requires ongoing approaches. A recent study reveals that patients who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who end traditional lifestyle programs. Published data in a major medical journal shows that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit. "People using such treatments should be informed of the risk of quick weight regain when the treatment concludes," cautioned expert Dr. Susan Jebb. That rate of regain suggests a reversion to original mass in about one and a half years. Comparing Treatments The analysis, which examined 37 of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills. Researchers point out that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 100 grams monthly—once they finish. Understanding the Fast Regain Nutrition scientists propose the mode of action of the jabs explains the heightened weight return. The injections imitate a body's own chemical called GLP-1, which helps regulate appetite. "Long-term administration of the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' means hunger is unsuppressed, making binge eating a significant risk." A Lifelong Disease? The NHS advise the injections for people with weight-linked health risks, alongside prescribed lifestyle changes. Professionals contend that, given the significant potential of relapse, the therapy should be considered life-long. This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," akin to managing diseases like hypertension. Patient Accounts People who have discontinued the medication explain a sudden resurgence of hunger. "It felt as if a switch that goes on and I was suddenly extremely hungry," said a patient. This challenge is worsened if users have not adopted sustainable lifestyle or habit modifications during treatment. Significant Interest Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial. Adoption is greater among women compared to males. The 40s and 50s age group shows the highest usage rates. A large proportion access the medications through private healthcare rather than public health services. In conclusion, researchers emphasize that while these medications are effective agents for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle changes.
Weight management often requires ongoing approaches. A recent study reveals that patients who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who end traditional lifestyle programs. Published data in a major medical journal shows that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit. "People using such treatments should be informed of the risk of quick weight regain when the treatment concludes," cautioned expert Dr. Susan Jebb. That rate of regain suggests a reversion to original mass in about one and a half years. Comparing Treatments The analysis, which examined 37 of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills. Researchers point out that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 100 grams monthly—once they finish. Understanding the Fast Regain Nutrition scientists propose the mode of action of the jabs explains the heightened weight return. The injections imitate a body's own chemical called GLP-1, which helps regulate appetite. "Long-term administration of the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' means hunger is unsuppressed, making binge eating a significant risk." A Lifelong Disease? The NHS advise the injections for people with weight-linked health risks, alongside prescribed lifestyle changes. Professionals contend that, given the significant potential of relapse, the therapy should be considered life-long. This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," akin to managing diseases like hypertension. Patient Accounts People who have discontinued the medication explain a sudden resurgence of hunger. "It felt as if a switch that goes on and I was suddenly extremely hungry," said a patient. This challenge is worsened if users have not adopted sustainable lifestyle or habit modifications during treatment. Significant Interest Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial. Adoption is greater among women compared to males. The 40s and 50s age group shows the highest usage rates. A large proportion access the medications through private healthcare rather than public health services. In conclusion, researchers emphasize that while these medications are effective agents for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle changes.